MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of “Buy” by Analysts

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been given an average recommendation of “Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $83.20.

Several analysts recently commented on MLTX shares. Needham & Company LLC lifted their price objective on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Finally, The Goldman Sachs Group cut their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

MoonLake Immunotherapeutics Trading Down 4.5 %

MoonLake Immunotherapeutics stock opened at $38.03 on Monday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -29.48 and a beta of 1.31. The stock has a fifty day simple moving average of $45.10 and a two-hundred day simple moving average of $48.63. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). On average, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth about $1,091,000. Jefferies Financial Group Inc. bought a new position in shares of MoonLake Immunotherapeutics during the fourth quarter valued at approximately $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company’s stock valued at $2,287,000 after buying an additional 6,422 shares during the last quarter. Woodline Partners LP grew its stake in shares of MoonLake Immunotherapeutics by 26.3% during the fourth quarter. Woodline Partners LP now owns 293,535 shares of the company’s stock valued at $15,895,000 after buying an additional 61,105 shares during the last quarter. Finally, Wexford Capital LP grew its stake in shares of MoonLake Immunotherapeutics by 71.4% during the fourth quarter. Wexford Capital LP now owns 24,000 shares of the company’s stock valued at $1,300,000 after buying an additional 10,000 shares during the last quarter. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.